To include your compound in the COVID-19 Resource Center, submit it here.

Akcea cutting workforce by 10% after Waylivra CRL

Akcea Therapeutics Inc. (NASDAQ:AKCA) will reduce its workforce by about 10% following receipt of a complete response letter from FDA for

Read the full 217 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE